Together, we can transform the future of cancer care.
Tracking early stage breast cancer with ultrasensitive ctDNA
Information for patients with breast cancer
Monitoring therapy response with ultrasensitive ctDNA across cancer types
Ultrasensitive ctDNA detection in early-stage lung cancer
Personalis is transforming the development of next-generation therapies.
The power of using a non-invasive test to actively manage a patient’s disease by detecting residual or recurrent disease as early as possible is making these tools an essential part of cancer care. We believe the key to delivering on the promise of liquid biopsy is technologies that detect, quantify, and analyze circulating tumor DNA (ctDNA) from only a small amount of blood. Personalis is at the forefront of developing technologies that increase the potential for tumor detection with the goal of prolonging patient survival.
Our patented approach to highly sensitive molecular residual disease (MRD) detection and quantification goes above and beyond whole-exome based approaches.
From a single assay, our variant-tracking technology allows you to track and annotate individual variants over the whole evolution of a cancer patient’s trajectory.
